stockrowBioNTech SE Sponsored ADR
BNTX Healthcare Biotechnology
BioNTech SE Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 9.07% from fiscal 2024.
- Revenue
- −16.4%
- EPS
- +708.4%
- Free cash flow
- −123.8%
- Total debt
- +44.4%
Quarter to September 2026, against a year earlier
Follow BNTX
Alert me
BioNTech SE Sponsored ADR (BNTX) Net income
BioNTech SE Sponsored ADR's net income for fiscal 2025 was −$1.2B, compared with −$733.3M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$1.6B. Over the past ten years it has ranged from −$1.2B (fiscal 2025) to $17.8B (fiscal 2021) — the current reading is the lowest in ten years. Net income has fallen for 4 consecutive fiscal years. BioNTech SE Sponsored ADR ranks 603rd of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$1.2B | — |
| FY2024 | −$733.3M | — |
| FY2023 | $1.3B | (90.59%) |
| FY2022 | $13.6B | (23.33%) |
| FY2021 | $17.8B | — |
| FY2020 | −$166.5M | — |
| FY2019 | −$201.0M | — |
| FY2018 | −$56.3M | — |
| FY2017 | $0.00 | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | $272.2M | — |
| Jun 2026 | −$994.0M | — |
| Mar 2026 | −$664.9M | — |
| Dec 2025 | −$226.4M | — |
| 26 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| ALNY Alnylam Pharmaceuticals, Inc. compare | $2.6B |
| GMAB Genmab A/S Sponsored ADR compare | $906.0M |
| EXEL Exelixis, Inc. compare | $885.1M |
| ASND Ascendis Pharma A/S compare | $865.9M |
| INCY Incyte Corporation compare | $403.4M |
| ROIV Roivant Sciences Ltd. compare | −$414.6M |
| BBIO BridgeBio Pharma, Inc. compare | −$577.6M |
| INSM Insmed, Inc. compare | −$605.6M |
| BNTX BioNTech SE Sponsored ADR | −$1.6B |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on BNTX
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Beneish M-score
- The full statement